Kestra Medical Reports 63% Revenue Surge on Assure System Adoption
Key Takeaways
- Kestra Medical (KMTS) delivered a strong Q3 2026 performance, highlighted by a 63% year-over-year revenue increase and the ninth consecutive quarter of gross margin expansion.
- While net losses widened to $34.2 million due to aggressive sales force expansion, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.
Mentioned
Key Intelligence
Key Facts
- 1Revenue grew 63% year-over-year to $24.6 million in Q3 2026
- 2Gross margin reached 52.6%, marking the ninth consecutive quarter of expansion
- 3Assure system prescriptions surpassed 5,400, a 58% increase from the prior year
- 4Company maintains a strong cash position of $291 million following a December equity offering
- 5Sales force expansion target set at 130 active territories by April 2026
- 6Newly added to the U.S. Department of Veterans Affairs Federal Supply Schedule
| Metric | ||
|---|---|---|
| Total Revenue | $24.6M | $15.1M |
| Gross Margin | 52.6% | 43.6% |
| Net Loss (GAAP) | $34.2M | $21.8M |
| In-Network Mix | ~82% | ~70% |
| Conversion Rate | 46% | 43% |
Analysis
Kestra Medical (KMTS) demonstrated significant momentum in its fiscal third quarter of 2026, reporting a 63% year-over-year revenue surge to $24.6 million. This growth was primarily fueled by a 58% increase in prescriptions for its flagship Assure system, a wearable cardioverter defibrillator (WCD) designed to protect patients at risk of sudden cardiac arrest. The results underscore Kestra’s successful penetration into the high-stakes cardiac monitoring market, where it competes for market share through technological differentiation and an expanding commercial footprint.
A standout metric in the quarter was the gross margin, which reached 52.6%. This represents a 900-basis-point improvement over the prior year and the ninth consecutive quarter of sequential expansion. Chief Financial Officer Vaseem Mahboob attributed this trend to a more favorable in-network billing mix, which has climbed to the low 80% range from approximately 70% at the time of the company’s initial public offering. This shift is critical for medical device companies, as in-network status typically leads to higher revenue per unit and more predictable reimbursement cycles.
Kestra Medical (KMTS) demonstrated significant momentum in its fiscal third quarter of 2026, reporting a 63% year-over-year revenue surge to $24.6 million.
Operational efficiency also saw a boost, with the prescription-to-revenue conversion rate rising to 46%, up from an adjusted 43% a year ago. This improvement reflects the company's efforts to streamline its fill rate and benefit identification number (BIN) rate, which are essential for navigating the complex landscape of insurance approvals. By improving these back-end processes, Kestra is ensuring that a higher percentage of prescribed devices actually reach patients and generate revenue, a key hurdle for many early-stage med-tech firms.
Strategic expansion remains a top priority for CEO Brian Webster. The company ended the calendar year with approximately 100 active sales territories and is on track to reach 130 by the end of the fiscal year in April. This aggressive hiring is a primary driver of the $47.7 million in operating expenses, which contributed to a GAAP net loss of $34.2 million for the quarter. While the loss widened from $21.8 million in the previous year, the company’s cash position remains robust at $291 million, bolstered by a successful equity offering in December. This capital provides Kestra with a significant runway to continue its market-share offensive without immediate liquidity concerns.
What to Watch
Two major regulatory and payer milestones were highlighted as future growth catalysts. First, Kestra was added to the U.S. Department of Veterans Affairs’ (VA) Federal Supply Schedule. This grants the company direct access to VA hospitals nationwide, a massive and stable market segment that often serves as a bellwether for broader clinical adoption. Second, the company achieved managed Medicaid provider status in Florida, signing agreements with two of the state's four largest plans. These developments not only expand the potential patient population but are also expected to support continued gross margin improvements as the payer mix matures.
Looking ahead, investors will be watching Kestra’s ability to maintain its margin expansion trajectory while scaling its sales force. The transition from 100 to 130 territories is a 30% increase in headcount that will test the company’s management and training infrastructure. However, with a strong cash balance and increasing payer acceptance, Kestra appears well-positioned to transition from a high-growth disruptor to a more established player in the cardiac monitoring space. The focus for the upcoming fourth quarter will likely be on the integration of these new territories and the initial revenue contribution from the VA and Florida Medicaid channels.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |